Bioxyne (ASX:BXN) has announced a $50 million exclusive medicinal cannabis supply agreement with German pharmaceutical company ADREXpharma. This two-year contract, facilitated through Bioxyne’s wholly-owned subsidiary Breathe Life Sciences, marks a strategic expansion into Germany, which is currently Europe’s largest and most developed medicinal cannabis market.
The agreement focuses on the distribution of BLS’s premium, Australian GMP-manufactured cannabis flower and associated products, establishing a sales pathway into the European Union. The financial structure of the deal offers substantial near-term revenue visibility for Bioxyne, as detailed in the Grafa report.
Terms of the Medicinal Cannabis Supply Agreement
The agreement includes an initial $25 million minimum commitment from ADREXpharma within the first 12 months. This commitment features an automatic renewal clause for an additional 12 months, bringing the total valuation of the contract to $50 million. This structure provides Bioxyne with a predictable revenue stream over the initial two-year period, subject to ADREXpharma meeting its purchase obligations.
Article by Hemp Gazette – Read more: https://hempgazette.com/news/bioxyne-german-medicinal-cannabis-supply-deal/